Using MRD results to guide extra treatment after breast surgery
Part of Cancer, Skin clinical trials.
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- You have confirmed invasive breast cancer that can be removed with surgery and has not spread
- You have not had anti-breast cancer whole-body treatment yet, and you plan to have both surgery and systemic (whole-body) therapy
- Your general health and strength are fairly good (ECOG performance status 0 to 2)
- Your blood counts, liver, and kidney tests are within acceptable ranges
- You can give informed consent and are able to safely take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
This study tests an additional treatment after surgery for stage II–III non-small cell lung cancer that may still have a chance of coming back (called MRD positive). It aims to see if this extra treatment reduces recurrence risk.
This study is looking at a test called MRD (minimal residual disease) to see if it can guide decisions about local treatments (like surgery or radiation) for people with breast cancer that has spread to a few spots. It may help doctors know when to use these treatments and when to wait.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
This study looks at how well targeted therapies work for people with colorectal cancer who have minimal residual disease (MRD, tiny amounts of cancer left after treatment) detected by a blood test. It is for people who have a specific genetic change (biomarker) in their tumor and have not been treated with the targeted therapy for that biomarker before.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.